Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

Fig. 1

Vemurafenib partially inhibits cell proliferation, cell cycle progression and ERK signaling in BRAF V600E thyroid carcinoma cell lines. a, b Growth rate (a) and cell viability (b) in BRAF V600E BHT101, FRO and BCPAP thyroid carcinoma cell lines and BRAF-wild type WRO cells treated with 1 and 10 μM PLX4032. c Cell cycle distribution in BRAF V600E BHT101, FRO and BCPAP thyroid carcinoma cell lines and BRAF-wild type WRO cells exposed to 10 μM PLX4032 for 15 h. a–c Statistical significance respect to each untreated control: *p < 0.05; **p < 0.005; ***p < 0.0005. d ERK and phosphoERK immunoblot analysis in BRAF V600E BHT101, FRO and BCPAP thyroid carcinoma cell lines and BRAF-wild type WRO cells exposed to 10 μM PLX4032 for 1 h

Back to article page